Phosphocol P 32 Linked to Risk Of Leukemia In Children

Off-Label Use of the Drug for Intra-articular Injections the Cause

The Food and Drug Administration has issued a Safety Alert regarding the unapproved use of Phosphocol P 32 (Chromic Phosphate P 32 Suspension) in children.

Two children with hemophilia, aged 9 and 14, who were treated with the drug developed acute lymphocytic leukemia with within one year following intra-articular injections. Phosphocol P 32 is not approved for use for intra-articular injection, or treating bleeding between the joints that is caused by hemophilia. The product labeling has been revised to warn health care professionals of this risk.

SEPT-19-08: Phosphocol P 32- Risk Of Leukemia Associated With Off-Label Intra-articular Use In Children [FDA: PHOSPHOCOL P 32 ]

Legal Help

If you or a loved one has suffered ill health or injury as a result of exposure to this drug, please click the link below to send your complaint to a lawyer to evaluate your claim at no cost or obligation.
Published on Sep-19-08